The 2026 GU ASCO annual meeting featured a testicular cancer session and a presentation by Dr. Jennifer King discussing a ...
In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.
Based on the NCCN 1.2026 guidelines for the management of CSI seminoma, surveillance is strongly preferred for pT1-pT3 tumors, and the NCCN does not recommend risk-adapted treatment for CSI seminoma ...
A new study co-led by WEHI has found a simple blood test can help identify the early-stage testicular cancer patients who are ...
News Medical on MSN
Blood test shows promise in forecasting outcomes for germ cell tumors
Can fragments of tumor DNA in the blood predict whether chemotherapy will be effective? Researchers at the Princess Máxima ...
Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. Data were available on 5,202 patients with nonseminomatous GCT ...
Although pediatric cancer is rare, it is the leading cause of death by disease in children, according to the National Institutes of Health (NIH). Over 16,000 children in the United States are ...
A study conducted by the Molecular Oncology Research Center (CPOM) at Hospital de Amor in Barretos (formerly Barretos Cancer Hospital) in the state of São Paulo, Brazil, has identified possible ...
The difference in the odds of development of bleomycin pulmonary toxicity in patients with germ cell tumors and Hodgkin’s lymphoma receiving granulocyte colony-stimulating factor alongside bleomycin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results